These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37140899)

  • 1. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
    Heiduk M; Klimova A; Reiche C; Digomann D; Beer C; Aust DE; Distler M; Weitz J; Seifert AM; Seifert L
    Clin Cancer Res; 2023 Jul; 29(14):2638-2650. PubMed ID: 37140899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy.
    Jiang F; Mao M; Jiang S; Jiao Y; Cao D; Xiang Y
    Int Immunopharmacol; 2024 Jan; 127():111381. PubMed ID: 38150880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.
    Pearce H; Croft W; Nicol SM; Margielewska-Davies S; Powell R; Cornall R; Davis SJ; Marcon F; Pugh MR; Fennell É; Powell-Brett S; Mahon BS; Brown RM; Middleton G; Roberts K; Moss P
    Cancer Immunol Res; 2023 Apr; 11(4):435-449. PubMed ID: 36689623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
    Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
    Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1
    Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
    Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
    Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
    Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased frequency of TIGIT
    Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
    Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral TIGIT
    Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
    Lee WJ; Lee YJ; Choi ME; Yun KA; Won CH; Lee MW; Choi JH; Chang SE
    J Am Acad Dermatol; 2019 Jul; 81(1):219-227. PubMed ID: 30880064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
    Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher frequency of peripheral blood CD103
    Liu L; Lai W; Zhuo X; Chen S; Luo X; Tan H
    Front Immunol; 2024; 15():1437726. PubMed ID: 39391310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.
    Piovesan D; de Groot AE; Cho S; Anderson AE; Ray RD; Patnaik A; Foster PG; Mitchell CG; Lopez Espinoza AY; Zhu WS; Stagnaro CE; Singh H; Zhao X; Seitz L; Walker NP; Walters MJ; Sivick KE
    Cancer Res; 2024 Jun; 84(12):1978-1995. PubMed ID: 38635895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.
    Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
    Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
    Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
    Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
    Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.